MOH · Molina Healthcare, Inc. · Stock research

Current Thesis

June's momentum leg the 2026-06-10 Illinois HealthChoice Medicaid win plus BofA's ~2026-06-24 double-upgrade (Underperform→Buy, $152→$250) that broke MOH out of its $188–192 chop to a $229.74 close (2026-06-26) has matured into a wait-for-the-print consolidation. Through July the rest of the sell-side raised targets into the price: RBC $248 (07-09), TD Cowen $230 (07-14), Truist $250 (07-14), Wells Fargo $235 (07-13). But every one of those raises kept a neutral rating (Hold/Equal-Weight/Sector-Perform), and Barclays cut its target to $184 while staying Underweight (07-09). The Medicaid-margin-trough recovery is intact, but it is now fully re-rated and sitting on a violent-history Q2 print (2026-07-22 after close). The read is a coiled pre-earnings range, not an entry zone: buying two trading days ahead of a binary this jumpy is a coin-flip on the tape, not on the thesis.

Bullish and bearish views on Molina Healthcare, Inc.

The model's bull view on Molina Healthcare, Inc. (MOH), in brief: BofA double-upgrade (~2026-06-24) anchors the multi-year ramp: Underperform→Buy, PT $152→$250, EPS modeled to ~$30 by 2029 vs Street ~$17.32 framing the $5 trough as the floor of an earnings normalization, "more a matter of time and math." July target cluster validates the… The bear view: Targets caught up to price, ratings did not. Both cases follow in full.

Bull Case

• BofA double-upgrade (~2026-06-24) anchors the multi-year ramp: Underperform→Buy, PT $152→$250, EPS modeled to ~$30 by 2029 vs Street ~$17.32 framing the $5 trough as the floor of an earnings normalization, "more a matter of time and math."
• July target cluster validates the level: even neutral-rated desks now peg fair value at $230–250 (RBC $248 07-09, Truist $250 07-14, Wells Fargo $235 07-13, TD Cowen $230 07-14). The June breakout is no longer a lone-analyst pop.
• Illinois HealthChoice award (2026-06-10): one of six plans across ~3.1M beneficiaries a concrete retention/growth datapoint under the revenue base that fed the breakout.
• Q1 2026 stabilization (late Apr): adj EPS $2.35, consolidated MCR 91.1%, Medicaid MCR 92.0%, FY26 reaffirmed ~$42B premium revenue / ≥$5.00 adj EPS, with management calling medical-cost trend "moderately favorable."
• 2027 rate catch-up: CMS lifted 2027 rates (flagged ~2026-04-23) against a sector underfunded ~300–400bps; 2026 is the called trough, 2027–28 the normalization. Investor Day (2026-05-08) set a $25 adj-EPS-by-2029 target.

Bear Case

• Targets caught up to price, ratings did not. July's raises to $230–250 all held Hold/EW/SP desks now underwrite the price but not more upside while Barclays cut to $184/Underweight (07-09). A $184–250 dispersion is low conviction on direction, and PT-catch-up after a +20% run is late-cycle validation.
• Q2 print (2026-07-22) is a binary with brutal history. Q4 2025 was an adjusted loss of -$2.75/sh and a guide-slash to ≥$5.00 from ~$13.71 consensus; the stock fell 28%. One quarter of "moderately favorable" trend (Q1's 92.0% Medicaid MCR still sits well above healthy high-80s) does not prove durable cost control into a high-bar number.
• Peer warning (2026-07-15): Elevance's outlook boost disappointed and the stock sank evidence that managed-care cost trend is still pressured heading into MOH's own print.
• ACA pressure persists: enhanced premium tax credits expired end-2025; WSJ (2026-07-08) reports insurers seeking big rate hikes again; Marketplace enrollment is projected 22.3M→~17.5M (-25%) into 2026, an adverse-selection headwind to Molina's Marketplace book.
• Redetermination overhang: new twice-a-year Medicaid eligibility checks begin December 2026 (flagged 2026-07-16) a membership-attrition catalyst into 2027.
• Index-flow overhang: an S&P reconstitution (announced 2026-07-16) moves MOH into the S&P MidCap 400 a marker that its ~$13B cap has fallen below the S&P 500 floor since the 2025 collapse, and a modest forced-selling cross-current from S&P 500 trackers landing near the print window.

Setup & Price Structure

• Breakout structure: cleared the $188–192 chop through the $205–210 shelf to a $229.74 close (2026-06-26, +6.3% on the day), ~+20% in three weeks.
• Now consolidating just under the $230–250 target ceiling and extended above the $188–192 base; the $205–210 shelf is the first support and the late-June gap-fill zone.
• Momentum leg is spent for now targets bracket spot, ratings are neutral, one desk is outright bearish. The tape reads as a coiled pre-earnings range rather than an accelerating trend.
• Two overlapping cross-currents hit the same window: the 2026-07-22 print and the S&P MidCap 400 index rebalance.
• No clean fresh entry exists inside three trading days of the print.

Catalyst Calendar (next 30 days)

• 2026-07-22 (after close) Q2 2026 earnings: THE binary. Medicaid MCR trend and FY26 ≥$5.00 adj-EPS confirmation vs cut.
• 2026-07-23 8:00 ET Q2 earnings call.

Elapsed catalysts

• ~2026-07-16 → late July S&P MidCap 400 index change effective at the July rebalance; forced-flow window. _(passed 3d ago)_
• Ongoing ACA 2027 rate-filing headlines (WSJ 2026-07-08); any enhanced-subsidy-extension legislation is a re-rate trigger. _(passed 11d ago)_
• December 2026 (dated 2026-07-16, beyond 30d) Medicaid twice-a-year eligibility checks begin; redetermination attrition catalyst worth pre-positioning around. _(passed 3d ago)_

What Would Change Our Mind

• Thesis-break level: a weekly close below $205 fills the late-June breakout gap and reverts MOH into the $188–192 chop, ending the momentum leg.
• Fundamental break: Q2 Medicaid MCR re-expanding above ~93%, or a FY26 adj-EPS guide cut below $5.00 either says the cost trend is re-accelerating and the trough thesis is broken.
• Bull re-confirmation: a post-print hold above $210 with Medicaid MCR compressing toward the low-90s/high-80s and FY26 reaffirmed would re-open the recovery as a multi-quarter fundamental hold.
• Theme confirmation: actual rating upgrades off Hold (not just target raises) would signal the narrative is still accelerating rather than saturating.

Correlation Notes

• Managed-care cohort CNC (Centene), ELV (Elevance), UNH, HUM: MOH trades with the group's Medicaid cost-trend read, and Elevance's 2026-07-15 disappointment is a direct negative peer signal into the print. BofA paired MOH with CNC as top 2027-margin-upside names.
• Policy beta: the Medicaid rate cycle (CMS 2027 rates), ACA subsidy legislation, and redetermination timelines make MOH a high-beta expression of federal healthcare policy more than a company-specific story.
• Index flow: the S&P 500 → MidCap 400 move (2026-07-16) is a technical, non-fundamental cross-current that muddies the post-print price signal.